The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.

The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014 Aug; 5(4):232-9.

View in: PubMed

subject areas

Adrenal Cortex Neoplasms
Adrenocortical Carcinoma
Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Female
Humans
Male
Middle Aged
Mitotane
National Cancer Institute (U.S.)
Neoplasm Recurrence, Local
United States
Young Adult

authors with profiles

Walter M. Stadler